James P. Quinlan - 22 Jul 2025 Form 4 Insider Report for Medicus Pharma Ltd. (MDCX)

Role
Chief Financial Officer
Signature
/s/ Raza Bokhari, as Attorney-in-Fact, for James P. Quinlan
Issuer symbol
MDCX
Transactions as of
22 Jul 2025
Transactions value $
$0
Form type
4
Filing time
24 Jul 2025, 17:17:18 UTC
Previous filing
31 Dec 2024
Next filing
14 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Quinlan James P. Chief Financial Officer 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W.CONSHOHOCKEN /s/ Raza Bokhari, as Attorney-in-Fact, for James P. Quinlan 24 Jul 2025 0002047493

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDCX Stock Option (right to buy) Award $0 +50K $0.00 50K 22 Jul 2025 Common Shares 50K $3.08 Direct F3
holding MDCX Stock Option (right to buy) 20K 22 Jul 2025 Common Shares 20K $2.75 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F2 The board of directors of Medicus Pharma Ltd. (the ?Board?) approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest quarterly in four equal installments over one year from the initial grant date of December 17, 2024. All these options are now vested.
F3 The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.